Cellceutix Pharmaceuticals, Inc., an emerging bio-pharmaceutical company, is focused on developing small molecule therapies in areas of unmet medical need. The company’s primary efforts are in cancer and inflammatory disease. Cellceutix intends to spend most of its time initially on lead product Kevetrin, which is being developed for drug-resistant cancers.
Developing the highest quality data and intellectual property to support Kevetrin, the company aims to move it as quickly as possible along the regulatory pathway. Cellceutix also has five other exciting compounds in its pipeline that will be progressed as resources become available.
The company is open to new partnerships that compliment its business strategy, technology and mission. In a growing industry with quickly advancing technologies for such things as drug delivery, biomarkers, etc., partnerships have become critical for advancing the development process as well as providing business opportunities.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment